Unraveling Diabetic Vascular Calcification: A Key Role for BCAT2
Diabetic macrovascular complications stand as a primary cause of death and disability among diabetes patients. At the heart of this challenge lies vascular calcification, a critical pathological mechanism that stiffens arteries, reduces their compliance, and significantly elevates the risk of atherosclerotic plaque rupture and acute cardiovascular events. Diabetic patients uniquely exhibit larger necrotic cores and extensive calcification in coronary artery atherosclerotic plaques compared to non-diabetic individuals.
Vascular calcification is an active process, involving the osteoblastic differentiation and mineralization of vascular smooth muscle cells (VSMCs). Despite its profound impact, the precise molecular mechanisms driving this process within diabetic atherosclerotic plaques have remained largely unclear, leaving a void in effective interventional strategies.
Identifying Potential Targets
In a significant stride toward understanding this complex issue, researchers from Prof. Zhongqun Wang's team at the Affiliated Hospital of Jiangsu University undertook comprehensive spatial metabolomics and single-cell transcriptomics analyses. Their focus was on anterior tibial arteries obtained from diabetic foot amputations, aiming to pinpoint intervention targets for vascular calcification in diabetic atherosclerotic plaques.
The team's findings revealed a notable enhancement of branched-chain amino acid (BCAA) catabolism and an increased expression of BCAT2, a key metabolic enzyme in the BCAA catabolic pathway, specifically within VSMCs of calcified anterior tibial arteries from amputated diabetic foot patients.
BCAT2's Pivotal Role in Intraplaque Calcification
To directly investigate the role of BCAT2 in intraplaque calcification within the context of diabetes, the research team developed a specialized mouse model. They generated apolipoprotein E (ApoE) and VSMC-specific BCAT2 double knockout mice (ApoE⁻/⁻/BCAT2ΔSMC) and subsequently studied them in a diabetic atherosclerosis calcification model.
"Experimental results showed that VSMC-specific BCAT2 knockout significantly reduced vascular calcification severity, decreased calcium salt deposition, and suppressed the osteogenic phenotypic transition of VSMCs."
This critical evidence strongly suggested BCAT2's direct involvement in promoting vascular calcification in diabetic atherosclerosis.
Deciphering the Molecular Mechanism: The BCAT2-BCKA-Histone Propionylation Axis
Further in-depth investigations, utilizing RNA sequencing, revealed that Runx2 expression was markedly downregulated in VSMCs following BCAT2 knockout. Runx2 is a master regulator of osteogenic differentiation.
Delving deeper into the epigenetic regulation, Chromatin immunoprecipitation sequencing (ChIP-seq) and ChIP-qPCR data provided compelling evidence. They demonstrated that histone H3 lysine 23 propionylation (H3K23pr) levels in the RUNX2 promoter region significantly decreased after BCAT2 knockout, yet were upregulated with BCKA (branched-chain α-keto acid, a product of BCAA catabolism) supplementation. This established a clear link between BCAT2, BCKA, and epigenetic modifications influencing Runx2.
Crucially, silencing RUNX2 substantially abrogated the regulatory effect of the BCAT2-BCKA axis on VSMC osteogenic differentiation, confirming Runx2 as a vital downstream effector.
A New Horizon for Diabetic Vascular Calcification Treatment
This groundbreaking study marks the first time a regulatory role for BCAT2-mediated BCAA catabolism in VSMCs has been established in the progression of intraplaque calcification in diabetic atherosclerosis. It precisely clarifies the mechanism by which the BCAT2-BCKA-histone propionylation axis regulates VSMC osteogenic transdifferentiation and intraplaque calcification in diabetes.
"The research provides experimental evidence supporting targeted inhibition of BCAT2 as a strategy for precise prevention and treatment of intraplaque calcification in diabetes."
The findings lay a robust theoretical foundation for future prospects, envisioning the utilization of targeted BCAT2 inhibition as a precise treatment for this debilitating condition.